Silver Book Fact

Use of a monocolonal antibody with adjuvant chemotherapy in HER2+ individuals with operable cancer was associated with a 33 percent reduction in risk of death.

Romond, E, E Perez, J Bryant, V Suman, C Geyer, N Davidson, et al. Tastuzumab plus Adjuvant Chemotherapy for Operable HER-2 Positive Breast Cancer. NEJM. 2005; 353: 1673-84. http://www.nejm.org/doi/full/10.1056/NEJMoa052122

Reference

Title
Tastuzumab plus Adjuvant Chemotherapy for Operable HER-2 Positive Breast Cancer
Publication
NEJM
Publication Date
2005
Authors
Romond, E, E Perez, J Bryant, V Suman, C Geyer, N Davidson, et al.
Pages
1673-84
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Every additional dollar spent on newer, less toxic hormonal therapy for breast cancer patients has produced health gains valued at between $27.03 and $36.81.  
  • The overall five-year survival rate for women with invasive breast cancer is now 89 percent.  
  • Since the war on cancer was declared in 1971, our arsenal has tripled. New drugs accounted for around 50-60% of the increase in six-year cancer survival rates since 1975.…  
  • Widespread use of cancer vaccines could result in a cure of melanoma/renal cell carcinomas and a 25% boost in survival for all other cancers.  
  • Survival rates for colon cancer went from 41 percent to 63 percent between 1975 and 1995.